Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

NCT03377725

Myelodysplastic Syndromes P53 Mutation

WITHDRAWN PHASE3

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

NCT02190695

Acute Myeloid Leukemia Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia

COMPLETED PHASE2

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

NCT00382200

Myelodysplastic Syndromes

COMPLETED PHASE1/PHASE2

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00020969

Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

TERMINATED PHASE2

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

NCT01798901

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +7 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myelodysplastic syndromes (MDS) are hematological disorders characterized by ineffective hematopoiesis. DNA hypomethylating agents such as decitabine have been shown to have activity in this disorder by reversing the epigenetic mechanism of gene silencing.

Acute Myeloid Leukemia (AML) is a hematological disorder characterized by ineffective hematopoiesis and malignant expansion of clonal myeloid cells. In elderly patients (≥ 60 years old), MDS commonly precedes the diagnosis of AML. Standard therapy for AML consists of cytotoxic chemotherapy and is often followed with allogeneic stem cell transplantation. Unfortunately, elderly patients are often unable to tolerate such aggressive therapy.

Arsenic has also shown activity in patients with MDS and AML though modulation of apoptosis via increased oxidative stress. In preclinical modes, arsenic activity is related to the production of radical oxygen species that damage mitochondria. Cellular glutathione acts as a cellular antioxidant and can be depleted with the vitamin ascorbic acid which increases intracellular oxidative stress and sensitivity to arsenic trioxide induced apoptosis.

We are studying the combination of decitabine, arsenic trioxide and ascorbic acid, two primary agents and one vitamin all with different mechanisms of action in order to improve the response rate in patients with MDS and AML. This is an open-label, single-arm, single-center, dose escalation Phase I trial of decitabine, arsenic trioxide and ascorbic acid in patients with MDS, either de novo or secondary, fitting any of the FAB classifications and AML.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Level 1 Arsenic Trioxide & Decitabine

Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.

Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.

Group Type EXPERIMENTAL

Arsenic Trioxide

Intervention Type DRUG

Decitabine

Intervention Type DRUG

Dose Level 2 Arsenic Trioxide & Decitabine

Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.

Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.

Group Type EXPERIMENTAL

Arsenic Trioxide

Intervention Type DRUG

Decitabine

Intervention Type DRUG

Dose Level 3 Arsenic Trioxide & Decitabine

Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.

Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.

Group Type EXPERIMENTAL

Arsenic Trioxide

Intervention Type DRUG

Decitabine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arsenic Trioxide

Intervention Type DRUG

Decitabine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dacogen, Vitamin C and Trisenox Dacogen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. MDS (either de novo or secondary) fitting any of the FAB classifications or AML defined by FAB classification criteria. Patients with \< 5% bone marrow blasts must also meet one of the following criteria:

1. Symptomatic anemia with either hemoglobin \<10.0 g/dL or requiring red blood cell (RBC) transfusion
2. Thrombocytopenia with a history of two or more platelet counts \< 50,000 / µL or a significant hemorrhage requiring platelet transfusions, or
3. Neutropenia with two or more absolute neutrophil counts \< 1,000 /µL.

AML patients must also have a WBC \< 10,000µL and meet one of the following two criteria:
1. Age greater than or equal to 60 years
2. Relapsed AML and are not a candidate for cytotoxic chemotherapy.
2. ECOG performance status of 0-2.
3. Must give written informed consent indicating their awareness of the investigational nature of this study and its potential hazards.
4. Adequate renal and hepatic function (creatinine \< 1.5x institutional upper limit of normal, total bilirubin ≤ 1.5x institutional upper limit of normal, AST and ALT ≤ 2x institutional upper limit of normal).
5. Serum potassium \> 4.0 mEq/L, serum magnesium \> 1.8 mg/dL.
6. Life expectancy of at least 16 weeks.
7. Women of childbearing age must have a negative serum pregnancy test prior to initiating therapy.
8. Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial.
9. Men must be willing to avoid fathering a new child while receiving therapy with decitabine.
10. Greater than or equal to 18 years, no upper age limit
11. Individuals who are candidates for hematopoietic stem cell transplantation and who meet all other study criteria may participate in the study and receive intravenous decitabine in combination with arsenic trioxide and Ascorbic acid as a treatment prior to transplantation.

Exclusion Criteria

1. Known central nervous system (CNS) leukemia.
2. Previously received greater than or equal to 5 cycles of azacitidine (Vidaza®, Pharmion Corp., Boulder, CO) or decitabine (Dacogen®, MGI Pharma Inc. Bloomington, MN).
3. QTc \> 460 msec.
4. Known or suspected hypersensitivity to decitabine, arsenic or ascorbic acid.
5. Receiving any other investigational agents within 30 days of first dose of study drug.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure of NYHA class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
7. Known positive serology for HIV.
8. Had radiotherapy within 14 days prior to study enrollment.
9. Known presence of hepatic tumors.
10. \< 18 years of age
11. Exclude women who are pregnant or breast feeding.
12. Known history of glucose-6-phosphate deficiency (G6PD).
13. Currently taking a Class Ia or Class III antiarrhythmic or other medication causally associated with prolonging QTc.
14. Use of aspirin with platelet counts \< 50,000/µl.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No